According to a report by Clipperton finance, the health sciences sector experienced solid growth (100%) in Q2 2013 over the previous quarter with several large deals (>$50M) in \"Medtech\" and \"Biotech\".<\/p>\n
<\/p>\n
<\/p>\n
The health sector accounts for 29% of the total amount invested.<\/strong><\/p>\n The healthcare sector attracted a significant share of the pie in the second quarter of the year with a growth of 100% with $453M. The IT sector topped the ranking with 62% representing a decrease of 5%. The cleantech sector reached the same level as the previous quarter with 9%.<\/p>\n \"In Spain the sector has also accounted for a similar percentage of Venture Capital investments. In the second quarter there were 26 deals with \u20ac11M of investment. Significant was the sale of\u00a0Endosense<\/a><\/span>\u00a0owned by\u00a0Ysios<\/a><\/span>. A significant round is expected to take place in the coming months.\u00a0TCD Pharma<\/span>\"Diego Gutierrez, an expert in corporate finance, points out in\u00a0ABRA INVEST<\/a><\/span>.<\/p>\n Most relevant operations<\/strong><\/p>\n The largest operation has been carried out by\u00a0Auris Medical<\/a><\/span>\u00a0 $51M. The round was participated by\u00a0Sofinnova partners<\/span>\u00a0and\u00a0Sofinnova Ventures<\/a><\/span>. The company will devote the investment to the development of its hearing loss drugs.<\/p>\n In second place comes the operation carried out in\u00a0Opsona Therapeutics<\/span>\u00a0of $43M financed by\u00a0BB Biotech<\/a><\/span>Sunstone, Baxter, Amgen and EMBL Ventures. The company focuses on inflammatory anti-immune diseases.<\/p>\n